theMednet (@themednet) 's Twitter Profile
theMednet

@themednet

The clinical knowledge base for medicine.

ID: 535863995

linkhttp://www.themednet.org calendar_today25-03-2012 00:55:30

414 Tweet

1,1K Followers

1,1K Following

theMednet (@themednet) 's Twitter Profile Photo

🚨Today’s #ASTRO25 clinical trial session on Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer has concluded. Dr. Spratt is answering questions now

🚨Today’s #ASTRO25 clinical trial session on Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer has concluded.
 
Dr. Spratt is answering questions now
theMednet (@themednet) 's Twitter Profile Photo

⚡The #ASTRO25 session on Efficacy of Hypofractionated Stereotactic Radiotherapy with Different Dose Fractionation Regimens Combined with Concurrent Bevacizumab in Recurrent High-Grade Gliomas has concluded. Dr. Mahajan is answering questions now on theMednet. Head to the

⚡The #ASTRO25 session on Efficacy of Hypofractionated Stereotactic Radiotherapy with Different Dose Fractionation Regimens Combined with Concurrent Bevacizumab in Recurrent High-Grade Gliomas has concluded.

 Dr. Mahajan is answering questions now on theMednet.
 
Head to the
theMednet (@themednet) 's Twitter Profile Photo

🚨The #ASTRO25 session on Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL (Phase II trial by the International Lymphoma Radiation Oncology Group) has concluded. Dr. Kelsey is answering questions now on theMednet. Join the discussion →

🚨The #ASTRO25 session on Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL (Phase II trial by the International Lymphoma Radiation Oncology Group) has concluded.
 
Dr. Kelsey is answering questions now on theMednet.

Join the discussion →
theMednet (@themednet) 's Twitter Profile Photo

🚨The #ASTRO25 session on Toxicities and Quality of Life Following Observation or Radiation Therapy for Dupuytren's Disease in the International DEPART Randomized Trial concluded. Dr. Bajaj is answering questions now on theMednet. See the discussion → bit.ly/46tuHX2

🚨The #ASTRO25 session on Toxicities and Quality of Life Following Observation or Radiation Therapy for Dupuytren's Disease in the International DEPART Randomized Trial concluded.
 
Dr. Bajaj is answering questions now on theMednet.

See the discussion → bit.ly/46tuHX2
theMednet (@themednet) 's Twitter Profile Photo

⚡The #ASTRO25 session on Clinical Effectiveness of Single Course Low-Dose Radiation Therapy in Knee Osteoarthritis has concluded. Dr. Bajaj is answering questions now on theMednet. Join the Q&A here → bit.ly/46tuHX2

⚡The #ASTRO25 session on Clinical Effectiveness of Single Course Low-Dose Radiation Therapy in Knee Osteoarthritis has concluded.

Dr. Bajaj is answering questions now on theMednet.

Join the Q&A here → bit.ly/46tuHX2
theMednet (@themednet) 's Twitter Profile Photo

⚡The #ASTRO2025 plenary session on Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation has concluded. Dr. MacDonald is answering questions now on theMednet. Join the Q&A →

⚡The #ASTRO2025 plenary session on Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation has concluded.
 
Dr. MacDonald is answering questions now on theMednet.

Join the Q&A →
theMednet (@themednet) 's Twitter Profile Photo

🚨Today’s #ASTRO25 plenary session on Primary Results for the Phase III Trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO; CRUK/18/010) just concluded. Dr. Frank is answering questions now on theMednet. Head to the Q&A →

🚨Today’s #ASTRO25 plenary session on Primary Results for the Phase III Trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO; CRUK/18/010) just concluded.

Dr. Frank is answering questions now on theMednet.

Head to the Q&A →
theMednet (@themednet) 's Twitter Profile Photo

⚡The #ASTRO25 plenary session on Primary Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer just concluded. Dr. Abramowitz is answering questions now on theMednet. See the Q&A here →

⚡The #ASTRO25 plenary session on Primary Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer just concluded.

Dr. Abramowitz is answering questions now on theMednet.

See the Q&A here →
theMednet (@themednet) 's Twitter Profile Photo

⚡The #ASTRO25 plenary session on Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM) just concluded. Dr. Shih and Dr. Mehta are answering questions now on theMednet. Head to the Q&A →

⚡The #ASTRO25 plenary session on Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM)  just concluded.

Dr. Shih and Dr. Mehta are answering questions now on theMednet.

Head to the Q&A →
theMednet (@themednet) 's Twitter Profile Photo

Hepatology is LIVE on @theMednet! Explore expert-answered Q&A in liver disease and transplant hepatology. ➡️ themednet.org/topic/1140 #Hepatology #LiverTwitter #MedEd

Hepatology is LIVE on @theMednet!

Explore expert-answered Q&A in liver disease and transplant hepatology.

➡️ themednet.org/topic/1140

#Hepatology #LiverTwitter #MedEd
theMednet (@themednet) 's Twitter Profile Photo

🚨 New poster at #ACR25 🚨 theMednet + ACR piloted a way to extend conference learning: expert-led Q&A shared over 6–8 weeks. 👩🏻‍⚕️ 675 physicians engaged 📈 ~5K views 📃 345 CME credits See the poster 👉 bit.ly/4q1nxky

🚨 New poster at #ACR25 🚨 

theMednet + ACR piloted a way to extend conference learning: expert-led Q&A shared over 6–8 weeks.

 👩🏻‍⚕️ 675 physicians engaged
 📈 ~5K views
 📃 345 CME credits

See the poster 👉 bit.ly/4q1nxky
theMednet (@themednet) 's Twitter Profile Photo

📢 Live on theMednet: ACR 2025 Preview Q&A Topic: GLP-1 Agonists in Rheumatic Diseases & OA GLP-1s have transformed diabetes and obesity care – but what role might they play in rheumatic disease and osteoarthritis? As ACR 2025 approaches, our physician experts are weighing in.

📢 Live on theMednet: ACR 2025 Preview Q&A

Topic: GLP-1 Agonists in Rheumatic Diseases & OA

GLP-1s have transformed diabetes and obesity care – but what role might they play in rheumatic disease and osteoarthritis? As ACR 2025 approaches, our physician experts are weighing in.
theMednet (@themednet) 's Twitter Profile Photo

🚀 theMednet is headed to ACR Convergence 2025! We’re excited to connect with rheumatologists and our partners and share how theMednet extends the learning and collaboration that happens at ACR. We’ll also be presenting our research on extending conference learning through

theMednet (@themednet) 's Twitter Profile Photo

We’re kicking off ACR Convergence 2025 with one of our new favorite traditions — the theMednet ACR Community Breakfast! ☕️🥐 We’re celebrating the accomplishments of our rheumatology community and their contributions to advancing clinical knowledge. We look forward to seeing

We’re kicking off ACR Convergence 2025 with one of our new favorite traditions — the theMednet ACR Community Breakfast! ☕️🥐

We’re celebrating the accomplishments of our rheumatology community and their contributions to advancing clinical knowledge.

We look forward to seeing
theMednet (@themednet) 's Twitter Profile Photo

Representing theMednet team at #ACR2025! Great to see acknowledgment for theMednet as a leader in rheumatology education grow year over year! Thank you to Dr. Leverenz for highlighting theMednet at the session "Swipe Right on Rheumatology: Engaging Learners and Creating

Representing <a href="/themednet/">theMednet</a> team at #ACR2025!

Great to see acknowledgment for theMednet as a leader in rheumatology education grow year over year! 
Thank you to Dr. Leverenz for highlighting theMednet at the session "Swipe Right on Rheumatology: Engaging Learners and Creating
theMednet (@themednet) 's Twitter Profile Photo

Last Monday, we hosted our annual theMednet Breakfast at ACR in Chicago! It was a wonderful morning celebrating the accomplishments of our rheumatology community and connecting with colleagues who continue to advance clinical knowledge on theMednet and beyond. Thank you to

Last Monday, we hosted our annual theMednet Breakfast at ACR in Chicago!

It was a wonderful morning celebrating the accomplishments of our rheumatology community and connecting with colleagues who continue to advance clinical knowledge on theMednet and beyond.

Thank you to
theMednet (@themednet) 's Twitter Profile Photo

“theMednet makes it possible for gastroenterologists and hepatologists everywhere to learn from each other and hear from experts in this field, bridging the gap between evidence and real-world practice.” — Dr. Christopher Kasia, Deputy Editor for Hepatology Explore Hepatology

“theMednet makes it possible for gastroenterologists and hepatologists everywhere to learn from each other and hear from experts in this field, bridging the gap between evidence and real-world practice.”

— Dr. Christopher Kasia, Deputy Editor for Hepatology

Explore Hepatology
theMednet (@themednet) 's Twitter Profile Photo

"How do you approach the management of post-TIPS hepatic encephalopathy?" In a recent discussion on theMednet.org, an expert hepatologist shared their approach to this challenging and often recurrent complication. Full Q&A → themednet.org/question/23688 #Hepatology

"How do you approach the management of post-TIPS hepatic encephalopathy?"

In a recent discussion on theMednet.org, an expert hepatologist shared their approach to this challenging and often recurrent complication.

Full Q&amp;A → themednet.org/question/23688

#Hepatology